BTK inhibitor falters in multiple sclerosis trials

IF 28.2 1区医学 Q1 CLINICAL NEUROLOGY

Nature Reviews Neurology Pub Date : 2024-04-10 DOI:10.1038/s41582-024-00958-8

Heather Wood

引用次数: 0

Abstract

Findings of phase III trials of the Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis were recently presented at the ACTRIMS Forum.

查看原文本刊更多论文

BTK抑制剂在多发性硬化症试验中表现不佳

布鲁顿酪氨酸激酶抑制剂 evobrutinib 用于复发性多发性硬化症患者的 III 期试验结果最近在 ACTRIMS 论坛上公布。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Neurology 医学-临床神经学

CiteScore

29.90

自引率

0.80%

发文量

138

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Neurology aims to be the premier source of reviews and commentaries for the scientific and clinical communities we serve. We want to provide an unparalleled service to authors, referees, and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians working in the field of neurology. Our broad scope ensures that the work we publish reaches the widest possible audience. Our articles are authoritative, accessible, and enhanced with clearly understandable figures, tables, and other display items. This page gives more detail about the aims and scope of the journal.